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Abstract  
Magnetic	   resonance	   imaging	   (MRI)	   is	   a	   state-­‐of-­‐the-­‐art	   radiological	   imaging	   technique	   with	   a	  
pivotal	  role	  in	  the	  diagnosis	  and	  characterisation	  of	  heterogeneous	  MS	  lesions	  in	  clinical	  and	  basic	  
research.	   Various	   MRI	   methodologies	   such	   as	   conventional	   T1/T2	   contrast,	   contrast	   agent	  
enhancement,	   diffusion	   weighted	   imaging	   (DWI),	   magnetization	   transfer	   imaging	   (MTR)	   and	  
susceptibility	   weighted	   imaging	   (SWI)	   have	   been	   developed	   to	   diagnose	   and	   investigate	   the	  
severity	  of	  MS	  pathology,	  including	  the	  processes	  of	  vascularization,	  demyelination/remyelination	  
and	  damage	  to	  regional	  brain	  connectivity	  from	  permanent	  axonal	  loss.	  The	  broad	  spectrum	  of	  MS	  
pathology	  manifests	  in	  diverse	  patient	  MRI	  presentations	  and	  affects	  diagnostic	  accuracy.	  To	  study	  
specific	   aspects	   of	   the	   disease,	   several	   mouse	   models	   such	   as	   Experimental	   Autoimmune	  
Encephalomyelitis	  (EAE)	  and	  virus	  and	  toxin-­‐induced	  demyelination	  models	  have	  been	  developed	  
to	   explore	   the	   pathologies	   that	   are	   otherwise	   difficult	   to	   unambiguously	   determine	   in	   patients.	  
This	  review	  aims	  to	  provide	  an	  overview	  of	  recent	  developments	   in	  MRI	  methodology	  that	  have	  
been	   tailored	   to	   study	  specific	  aspects	  of	  MS	   in	  animal	  models	  and	   to	  describe	   their	   role	   in	   the	  
interpretation	   of	   pathology	   and	   their	   contribution	   to	   abnormal	   observations	   in	   patient	   MRI	  
examinations.	   Key	   aspects	   of	  MS	   have	   been	   investigated	   in	   various	  mouse	   animal	  models.	   For	  
example,	   the	   toxin-­‐induced	   cuprizone	   model	   has	   been	   used	   in	   assessing	   the	   MS-­‐related	  
demyelination	   and	   remyelination	   processes.	   In	   both	   animal	   models	   and	   MS	   patients,	   DWI	  
parameters	   such	  as	   radial	   diffusivity	   and	   fractional	   anisotropy	  are	  now	  established	  as	   surrogate	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biological	   markers	   of	   demyelination.	   These	   imaging	   techniques	   have	   all	   made	   significant	  
contributions	  to	  MS	  research	  in	  both	  preclinical	  and	  clinical	  environments.	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1. Introduction  
Multiple	  sclerosis	  (MS)	  can	  be	  defined	  as	  a	  chronic	  inflammatory	  demyelinating	  disease	  [1,	  2].	  It	  is	  
the	  most	  common	  central	  nervous	  system	  dysfunction	  that	  causes	  clinical	  disability	   in	  the	  young	  
adult	  population	  with	  the	  majority	  of	  the	  MS	  associated	  symptoms	  being	  either	  reversible,	  such	  as	  
diplopia	   (double	   vision),	   or	   irreversible,	   such	   as	   blindness	   [3,	   4].	   According	   to	   the	  MS	   Research	  
Australia	  website	  (http://www.msra.org.au/living-­‐ms),	  23,000	  people	   in	  Australia	  have	  been	  diagnosed	  
with	  MS	  and	  2.5	  million	  globally	  in	  recent	  years.	  Three	  out	  of	  every	  four	  MS	  cases	  are	  women	  due	  
to	  genetic	   factors.	  The	   incidence	  of	   the	  disease	   increases	  by	  7%	  annually,	  with	   the	   total	   cost	  of	  
health	  care	  in	  Australia	  for	  MS	  patients	  being	  approximately	  $2	  billion	  dollars	  [5].	  
The	  major	  cause	  of	  MS	  is	  not	  yet	  resolved,	  because	  the	  pathobiological	  mechanisms	  are	  not	  fully	  
understood.	   However,	   there	   are	   several	   factors	   that	  may	   predominately	   lead	   to	   higher	   disease	  
susceptibility.	  These	  include	  genetic,	  gender,	  ethnic	  and	  environmental	  factors	  [6].	  Genetic	  factors	  
could	  play	  a	  significant	  role	  because	  the	  existence	  of	  particular	  tissue	  type	  antigens	  such	  as	  HLA	  
(Human	  Leukocyte	  antigen)	  DR2	  and/or	  DW2	  in	  European	  Caucasian	  patients	  increases	  the	  risk	  of	  
developing	  MS	  [7].	  	  
MS	  is	  an	  autoimmune	  disease	  that	  targets	  myelin	  resulting	  in	  disruptions	  of	  nerve	  conduction	  and	  
neurotransmission	  [1,	  8,	  9].	  The	  disease	  initiates	  with	  inflammation	  and	  destruction	  of	  myelin	  that	  
normally	   provides	   protection	   for	   the	   brain	   and	   spinal	   cord	   nerve	   fibres	   [10].	   Once	   myelin	   is	  
destroyed,	   it	   is	   replaced	  by	  hardened	   sclerotic	   patches	  of	   tissue,	   known	  as	   sclerotic	   plaques	   [4,	  
11].	  The	  damage	  to	  the	  central	  nervous	  system	  is	  caused	  by	  autoimmune	  reactions,	  either	  through	  
T-­‐cells	  or	  an	  antibody-­‐mediated	   injury.	  However,	  MS	  may	   result	   from	   infectious	  agents,	   such	  as	  
human	  herpes	  virus	  	  (HHV	  6),	  an	  endogenous	  retrovirus	  and	  chlamydia	  pneumonia	  [7].	  	  
Using	   MRI,	   MS	   plaques	   are	   commonly	   observed	   in	   several	   areas	   of	   the	   brain,	   but	   the	   most	  
affected	   area	   is	   the	   white	   matter	   [12,	   13].	   Highly	   susceptible	   areas	   are	   the	   optic	   nerves,	  
periventricular	   area,	   corpus	   callosum,	   cerebral	   peduncle	   and	   spinal	   cord	   [14,	   15].	   According	   to	  
several	  post-­‐mortem	  studies	   [16-­‐19]	  and	   recent	  MR	   imaging	   studies	   [20-­‐23]	  MS	   lesions	  are	  also	  
present	  in	  grey	  matter.	  In	  addition,	  cortical	  lesions	  [24,	  25]	  have	  been	  detected	  by	  MRI	  with	  novel	  
neuroimaging	   techniques,	   either	   imaging	   at	   ultra-­‐high	   field	  or	   utilising	  phase	   sensitive	   inversion	  
recovery	  MRI	  [18,	  20,	  24,	  26,	  27].	  	  
Conventional	   MRI	   contrast	   mechanisms	   such	   as	   inversion	   recovery,	   T1,	   T2	   and	   T2*	   weighted-­‐
imaging	   have	   been	   used	   widely	   to	   detect	   MS	   pathology,	   however,	   they	   are	   non-­‐specific	   in	  
describing	  the	  progression	  of	  neural	  degeneration	  [13,	  15].	  More	  advanced	  MR	  imaging	  methods	  
have	  been	  developed	   to	   address	   these	   issues:	   (1)	  A	   combination	  of	   ultra-­‐high	   field	   scanners	   ≥7	  
tesla	  (T)	  for	  human	  [19,	  28,	  29]	  and	  ≥9.4T	  for	  animals	  [30-­‐33]	  and	  novel	  contrast	  agents	  such	  as	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ultra-­‐small	  iron	  oxide	  particles	  (USPIOs)	  enables	  better	  detection	  of	  early	  MS	  changes	  in	  the	  CNS	  
as	  well	  as	  depiction	  of	  small	   lesions	  within	  the	  subcortical	   layers	  [34].	  (2)	  Magnetization	  transfer	  
imaging	   (MTI)	   has	   been	   developed	   as	   a	   probe	   for	   assessment	   of	   myelin	   sheath	   integrity	   by	  
measuring	   the	   myelin	   macromolecular	   structures	   and	   myelin	   water	   function	   [35].	   (3)	   The	  
sensitivity	  of	  Susceptibility-­‐weighted	   imaging	   (SWI)	   to	   tissue	   iron	  content	  has	  been	  exploited	   for	  
detecting	  MS	  plaques	  and	  distinguishing	  non-­‐symptomatic	  white	  matter	   lesions	   from	  MS	   lesions	  
surrounding	   the	   central	   veins	   [36].	   (4)	  Diffusion-­‐weighted	   imaging	   (DWI)	   techniques	   allow	  early	  
detection	  of	  subtle	  changes	  in	  white	  and	  grey	  matter	  that	  appear	  normal	  in	  T1,	  T2-­‐weighted	  scans,	  
and	   DTI	   fibre-­‐tractography	   reveals	   deficits	   in	   neuronal	   connectivity	   [37].	   DWI	   methodology	   is	  
becoming	   increasingly	   important	   as	   diffusion	   parameters	   fractional	   anisotropy	   (FA)	   and	  
axial/radial	  diffusivity	  measures	  are	  central	  to	  assessment	  of	  MS	  pathology	  due	  to	  their	  specificity	  
in	  detecting	  the	  process	  of	  demyelination,	  axonal	  damage	  and	  injury	  [38].	  	  
2. Animal models of Multiple Sclerosis (MS) 
Experimental	   animal	  models	   are	   used	   to	   investigate	   and	   gain	   insights	   into	   the	   pathobiology	   of	  
complex	  human	  diseases	  [39].	  These	  models	  usually	  target	  a	  specific	  aspect	  of	  the	  disease	  rather	  
than	  attempting	  to	  replicate	  the	  full	  spectrum	  of	  the	  corresponding	  human	  disease	  [40].	  Although	  
an	  enhanced	  understanding	  of	  particular	  aspects	  of	  disease	  can	  be	  gained	  from	  in	  vitro	  and	  ex	  vivo	  
experimentation,	   in	   vivo	   experiments	   in	   animals	   are	   required	   to	   gain	   insight	   into	   the	   inter-­‐
relationships	  of	  multiple	  factors	  that	  contribute	  to	  complex	  pathobiological	  changes,	  such	  as	  the	  
relationship	  between	  neurodegeneration	  and	  MS	  progression	  [41].	  Research	  on	  MS	  pathobiology	  
has	   relied	   upon	   conventional	   diagnostic	   imaging,	   involving	   experimental	   animal	   sacrifice	   for	  
histological	   analysis	   at	   varying	   times	   throughout	   the	   disease	   course.	   However,	   as	   most	  
pathological	   processes	  during	   the	   course	  of	  MS	  are	  dynamic,	  monitoring	  of	  disease	  progression	  
requires	   longitudinal	   studies	   [31].	  MRI	   has	   played	   an	   increasingly	   pivotal	   role	   as	   a	   non-­‐invasive	  
imaging	  modality	  allowing	  longitudinal	  imaging	  of	  MS	  disease	  progression	  [39,	  42].	  
Rodent	  models	   have	   been	   developed	   to	   study	   the	   process	   of	   inflammation	   and	   demyelination	  
associated	   with	   MS	   in	   the	   central	   nervous	   system.	   The	   most	   commonly	   used	   models	   are	  
experimental	   autoimmune	   encephalomyelitis	   (EAE),	   Theiler’s	  murine	   encephalitis	   virus	   infection	  
(TMEV)	  and	  toxic	  demyelination	  models	   [41].	  There	   is	  no	  single	  animal	  model	   that	  can	   faithfully	  
reproduce	  all	  the	  pathological	  aspects	  of	  MS	  in	  humans.	  The	  available	  models	  complement	  each	  
other	  to	  enable	  investigation	  of	  various	  features	  commonly	  observed	  in	  the	  human	  condition	  [43].	  
2.1. Experimental Autoimmune Encephalomyelitis (EAE)  
Since	  its	  introduction	  by	  Rivers	  et	  al.	  in	  1930	  [44]	  EAE	  has	  become	  a	  widely	  used	  animal	  model	  for	  
multiple	  sclerosis.	   It	  can	  be	   induced	   in	  several	  mammalian	  species,	   including	  the	  mouse,	  rat	  and	  
primate	  [45].	  Induction	  of	  EAE	  is	  achieved	  by	  an	  injection	  of	  an	  emulsion	  comprising	  an	  adjuvant	  
and	   synthetic	   peptides	   derived	   from	   myelin	   proteins,	   such	   as	   myelin	   oligodendrocyte	   (MOG),	  
myelin	  basic	  protein	  (MBP)	  or	  the	  proteolipid	  protein	  (PLP).	  Alternatively,	   transgenic	  EAE	  can	  be	  
induced	  in	  mice	  by	  T	  cell	  transfer	  from	  EAE	  donors	  to	  native	  recipients	  and	  EAE	  will	  be	  produced	  
without	   further	   immunization	   [46].	   In	  most	  cases,	  EAE	   immunization	  will	   result	   in	   the	  activation	  
and	   expansion	   of	   the	   peripheral	   antigen	   specific	   T-­‐cells,	   which	   can	   penetrate	   the	   blood-­‐brain	  
barrier	   (BBB)	   and	   interact	   with	   specific	   myelin	   antigen	   inducing	   MS	   [47].	   In	   addition	   to	  
inflammation	  and	  demyelination,	  EAE	  is	  used	  to	  study	  acute	  and	  chronic	  axonal	  injuries.	  In	  the	  EAE	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model,	  macrophages	  have	  been	  suggested	  to	  play	  a	  vital	  role	   in	   inducing	  axonal	   injury,	  although	  
this	  has	  not	  been	  definitively	  confirmed	  [48].	  	  
The	  course	  of	  the	  EAE	  model	  of	  MS	  disease	  varies	  depending	  on	  the	   immunisation	  protocols,	  as	  
well	   as	   the	   choice	   of	   animal	   species	   and	   strain.	   In	   general,	   the	   acute	   phase	  of	   EAE	   induction	   is	  
associated	  with	  mononuclear	   cell	   infiltration	   into	   the	  CNS.	   This	   phase	   is	   followed	  by	   a	   recovery	  
period,	  called	  the	  remission	  stage.	   If	   the	  animal	  has	  not	   recovered,	   the	  chronic	  stage	   is	   reached	  











Figure	  1.	  The	  clinical	  course	  spectrum	  of	  EAE	  mouse	  model	   Immunisation	  of	  animals	  with	  myelin	  antigens	  produced	  
EAE	  cycle	  and	  could	  be	  correlated	  with	  clinical	  scores	  ranging	  from	  0	  to	  4,	  where	  0	  represents	  no	  clinical	  symptoms	  and	  
4	   refers	   to	   paralysis	   that	   is	   usually	   observed	   as	   a	   flaccid	   paralysis	   of	   the	   hind	   limbs.	   (A)	   Acute	   EAE	   followed	   by	  
remission,	   (B)	   chronic	   EAE	   without	   recovery,	   (C)	   Relapsing-­‐remitting	   EAE	   where	   animals	   developed	   relapses	   and	  
remissions	   with	   accumulated	   neurological	   deficits.	   (D)	   Omission	   of	   pertussis	   toxin	   will	   result	   in	   a	   reduction	   in	   the	  
clinical	   score	   compared	   with	   (A),	   and	   did	   not	   show	   extensive	   demyelination	   in	   the	   luxol	   fast	   blue	   (LFB)	   stain	   (E).	  
Injection	  of	  MOG	  at	  the	  onset	  of	  EAE	  exacerbated	  the	  clinical	  disease	  presentation,	  as	  shown	  in	  the	  LFB	  stain	  (F).	  Arrow	  
points	  to	  remnants	  of	  myelin	  [49].	  
There	  are	   three	   types	  of	  adjuvants	   included	   in	   immunization	  protocols	  used	  to	   induce	  EAE:	  Quil	  
Adjuvant	  (A),	  complete	  Freud’s	  adjuvant	  (CFA)	  and	  pertussis	  toxin,	  [50,	  51].	  A	  mild	  EAE	  model	  with	  
a	   relapsing	   remitting	   (RR)	   cycle	   followed	   by	   a	   complete	   recovery	   period	   can	   be	   induced	   using	  
MOG35-­‐55	   (myelin	   oligodendrocyte	   glycoprotein	   peptide	   sequence	   35-­‐55)	   and	  Quil	   A,	  which	   acts	  
once	   at	   the	   site	   of	   immunisation	   [52].	   CFA	   is	   an	   adjuvant	   prepared	   from	  killed	  mycobacteria	   in	  
water	  and	  oil	  emulsion	   [50].	  A	  chronic	  EAE	  model	   is	   induced	  by	   injection	  of	  MOG35-­‐55	  with	  CFA,	  
which	  slowly	  releases	  the	  antigen	  from	  the	  injection	  site	  [53].	  Pertussis	  toxin	  is	  generally	  required	  
to	   initiate	   T	   cell	   and	   B	   cell	   immune	   reactivity	   to	   the	   antigen.	   As	   a	   general	   role,	   adding	   a	   high	  
concentration	  of	  pertussis	  toxin	   in	  the	   immunisation	  protocol	   increases	  the	  disease	  severity	  to	  a	  
hyperacute	   stage,	  possibly	   through	  a	  non-­‐selective	  expansion	  of	  T-­‐cells	  and/or	  vascular	   changes	  
(increased	  BBB	  permeability)	  in	  the	  CNS	  [54].	  Severe	  EAE	  models,	  however,	  should	  be	  avoided	  as	  




Various	   EAE	   rodent	   models	   of	   MS	   have	   increased	   our	   collective	   understanding	   of	   the	  
immunopathology	  and	  neurodegenerative	  aspects	  of	  MS,	  which	  led	  to	  successful	  development	  of	  
three	   currently	   marketed	   therapeutic	   drugs,	   namely,	   glatiramer	   acetate,	   mitoxantrone	   and	  
natalizumab,	  all	  which	  have	  been	  approved	  by	  the	  FDA	  (The	  US	  Food	  and	  Drug	  Administration)	  for	  
clinical	  treatment	  [45,	  51].	  A	  limitation	  of	  EAE-­‐rodent	  models	  is	  that	  they	  do	  not	  adequately	  mimic	  
the	  auto	  immune	  factors	  that	  contribute	  to	  MS	  disease	  pathology	  [47].	  In	  EAE	  animal	  models	  CD4+	  
T-­‐cell	  predominate	  in	  CNS	  lesions,	  which	  has	  only	  been	  observed	  in	  a	  few	  patient	  cases	  [55]	  and	  
does	  not	  reflect	  the	  predominance	  of	  CD8+	  T-­‐cells	  and	  macrophages	  in	  MS	  lesions	  in	  humans	  [56].	  
2.2. Virus-induced demyelination model 
In	   the	   1980s,	   it	   was	   suggested	   that	   a	   combination	   of	   a	   certain	   genetic	   background	   and	   a	   viral	  
infection	  could	   increase	   the	   risk	  of	  developing	  MS	   [57,	  58],	  although	  at	   that	   time,	   there	  was	  no	  
virus	  identified	  to	  potentially	  induce	  MS.	  More	  recently	  [59-­‐61],	  correlations	  of	  EBV	  (Epstein-­‐Barr	  
Virus)	  infection	  with	  MS	  suggest	  EBV	  as	  a	  potential	  environmental	  factor.	  These	  findings	  have	  led	  
to	  the	  development	  of	  MS	  animal	  models	  using	  viral	   induction.	  The	  common	  model	   is	  the	  TMEV	  
(Theiler’s	  murine	  encephalomyelitis	  virus),	  which	  is	  induced	  by	  an	  intra-­‐cerebral	  injection	  of	  TMEV	  
into	  susceptible	  mouse	  strains.	  TMEV	  pathology	  is	  limited	  to	  the	  CNS	  with	  an	  extensive	  spinal	  cord	  
lesion	  [62].	  	  
TMEV	  infection	  can	  be	  highly	  or	  less	  virulent,	  for	  example,	  the	  immunisation	  of	  TMEV	  GD-­‐VII	  strain	  
produced	  fatal	  encephalitis,	  whereas	  the	  BeAn	  and	  Daniel	  TMEV	  strains	  are	  less	  virulent	  [63].	  The	  
TMEV	  model	   is	  suggested	  to	  be	  superior	   to	  the	  EAE	  model	   for	  assessment	  of	   treatment	  efficacy	  
due	  to	  better	  correlation	  with	  clinical	  MS	  [64].	  An	  example	  of	  successful	  application	  of	  the	  TMEV	  
model	  is	  in	  the	  development	  of	  anti-­‐glatiramer	  acetate	  antibodies	  as	  a	  remyelination	  agent	  [65].	  	  	  	  
TMEV	   can	   be	   used	   to	   produce	   a	   mono-­‐	   or	   a	   bi-­‐phasic	   MS	   disease	   course	   in	   susceptible	   mice.	  
During	  mono-­‐phasic	  disease,	  mice	  experience	  transient	  meningo-­‐encephalomyelitis	  that	  peaks	  by	  
approximately	   seven	   days	   with	   recovery	   during	   a	   three-­‐week	   period	   [66].	   The	   mono-­‐phasic	  
disease	   course	   is	   characterized	   by	   animal	   recovery	   in	   the	   absence	   of	   persistent	   neurological	  
impairments.	  In	  the	  case	  of	  the	  bi-­‐phasic	  disease	  course,	  it	  begins	  with	  a	  mono-­‐phasic	  stage	  that	  
subsequently	   develops	   into	   a	   chronic	   demyelination	   stage	   [67].	   MS	   lesions	   are	   commonly	  
observed	  in	  the	  spinal	  cord,	  akin	  to	  the	  EAE	  model	  [40,	  66,	  68].	  
In	  most	  cases,	  TMEV	  can	  produce	  chronic	  progressive	  MS,	  which	  mirrors	  chronic	  progressive	  MS	  in	  
humans.	  The	  TMEV	  mouse	  model	  offers	  several	  advantages;	  it	  is	  potentially	  able	  to	  mimic	  human	  
MS,	  in	  addition	  to	  modelling	  the	  autoimmune	  response	  [50].	  It	  also	  allows	  investigation	  of	  the	  role	  
of	  viral	   infection	   in	   the	  aetiology	  of	  MS	  and	   the	  worsening	  of	  MS	  clinical	   symptoms	   [61,	  64,	  68,	  
69].	  
2.3. Toxin-induced demyelination model 
Mouse	  models	  using	  toxin-­‐induced	  demyelination	  have	  been	  developed,	  not	  to	  mimic	  MS,	  but	  to	  
establish	   and	   investigate	   the	   process	   of	   demyelination	   and	   remyelination	   [70].	   Two	   toxins	   are	  
generally	  used	  to	  induce	  demyelination,	  viz	  lysolecithin	  and	  cuprizone.	  Lysolecithin	  is	  an	  activator	  
of	  phospholipase	  and	  cuprizone	  is	  a	  copper	  chelator	  [71].	  Lysolecithin	  acts	  as	  a	  detergent	  on	  the	  
myelin	  sheath,	  rather	  than	  having	  a	  secondary	  effect	  on	  oligodendrocytes	  [47].	  On	  the	  other	  hand,	  
a	  cuprizone-­‐induced	  copper	  deficit	   is	  thought	  to	  be	  detrimental	  to	  mitochondrial	   function	   in	  the	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brain.	   This	   will	   disturb	   the	   energy	   metabolism	   in	   the	   oligodendrocyte	   and	   cell	   function	   and	  
consequently	  lead	  to	  demyelination	  [70].	  	  
The	   injection	   of	   2	   μl	   of	   1%	   lysolecithin	   into	   the	   rodent	   spinal	   cord	   will	   produce	   focal	   areas	   of	  
demyelination	   [72].	   This	  model	   has	   been	   successfully	   applied	   in	   both	   rats	   and	  mice.	  During	   the	  
acute	  stage,	   spinal	  cord	   lesions	  are	  characterized	  by	   infiltrating	  T	  cells,	  B	  cells	  and	  macrophages	  
and	  according	  to	  Bieber	  et	  al,	  T	  cells	  are	  essential	  for	  the	  remyelination	  process	  [72].	   In	  general,	  
the	  lysolecithin-­‐induced	  toxin	  model	  can	  produce	  a	  minimum	  chronic	  lesion	  and	  full	  remyelination	  
occurs	  within	   five	   to	   six	  weeks.	   If	   the	   experimental	   animals	   are	   young,	   the	   repair	   process	  may	  
occur	  rapidly	  [73].	  	  	  	  
Cuprizone	   is	   the	   most	   frequently	   used	   toxin	   to	   study	   demyelination	   in	   mice	   [70,	   74].	  
Conventionally,	   the	   addition	   of	   0.2%	   cuprizone	   in	   the	   diet	   of	   young	   adult	  mice	   for	   four	   to	   five	  
weeks	  (acute)	  or	  12	  weeks	  (chronic)	  will	  produce	  focal	  demyelinated	  lesions	  within	  several	  white	  
matter	   structures,	   including	   the	   corpus	   callosum,	   internal	   capsule,	   cerebral	   peduncles,	   anterior	  
commissure	  and	  thalamic	  white	  matter	  [70,	  74].	  Once	  the	  cuprizone	  is	  removed	  from	  the	  diet,	  the	  
mice	  will	  progressively	  develop	  remyelination	  within	  three	  to	  four	  weeks	  [68].	  The	  toxin	  model	  is	  
potentially	   reproducible	   and	   hence	   useful	   for	   testing	   novel	   therapeutic	   approaches	   that	   can	  
suppress	   demyelination	   and	   accelerate	   remyelination	   [68,	   75].	   In	   Table	   1,	  we	  have	   summarized	  
commonly	  used	  rodent	  models	  of	  MS	  and	  their	  clinical	  features	  [68,	  75].	  	  
3. MRI studies of animal models of MS 
MS	   clinical	   studies	   require	   recruitment	   of	   large	   numbers	   of	   patients	   with	   long	   follow	   up	  
procedures	   and	   the	   patients	   must	   be	   grouped	   according	   to	   MS	   stage	   [76].	   However,	   animal	  
models	   of	   MS	   [77-­‐79]	   have	   better	   accessibility	   and	   their	   use	   has	   enhanced	   our	   collective	  
understanding	  of	  the	  pathological	  mechanisms	  underpinning	  demyelination	  and	  axonal	  damage	  in	  
the	  CNS.	  Animal	  studies	  allow	  monitoring	  of	  the	  environment	  as	  well	  as	  validation	  of	  experimental	  
results,	  which	  is	  more	  difficult	  to	  achieve	  in	  human	  studies.	  MS	  is	  a	  heterogeneous	  disease,	  and	  in	  
vivo	  MRI	  holds	  great	  potential	  as	  an	  assessment	  tool	  because	  it	  is	  non-­‐invasive	  and	  facilitates	  the	  
undertaking	  of	  longitudinal	  studies	  [31]	  including	  MRI	  assessments	  such	  as	  T1	  hypointensity	  and	  its	  
correlation	   with	   progression	   of	   neurological	   impairment	   [80].	   In	   conjunction	   with	   in	   vivo	   MR	  
imaging,	   ex	   vivo	   imaging	   provides	   higher	   resolution	  without	   restrictions	   upon	   experiment	   time,	  
allowing	   detection	   of	   more	   subtle	   changes	   [81].	   Table	   2	   summarizes	   MRI	   observations	   in	   MS	  
patients	   and	  mouse	  models	   and	   their	   correlations	  with	  MS	  pathology.	   Table	   3	   summarizes	  MRI	  
interpretations	  and	  their	  correlations	  with	  the	  pathological	  expectations.	  
3.1. Conventional MRI 
The	  MRI	   protocol	   for	   assessing	  MS	   patients	   often	   includes	   pre-­‐	   and	   post-­‐contrast	   T1-­‐weighted	  
imaging	  (T1	  WI),	  T2-­‐weighted	  imaging	  (T2	  WI),	  and	  fluid	  attenuated	  inversion	  recovery	  (FLAIR)	  [82].	  
At	  higher	  magnetic	   field	   (≥3T),	  Double	   Inversion	  Recovery	   (DIR)	  has	   recently	  been	  developed	   to	  
increase	   the	   sensitivity	   for	   detecting	   cortical	   lesions	   [15,	   20].	   These	   structural	   MR	   imaging	  
techniques	  have	  played	  an	   important	  role	   in	  the	  study	  of	  spatial	  and	  temporal	  characteristics	  of	  





Table	  1.	  Summary	  of	  rodent	  models	  of	  MS	  and	  clinical	  features	  
MS	  Model	  in	  
Mice	  
Method	  of	  induction	   Clinical	  significance,	  severity	   Reference	  
EAE	   MOG35-­‐55+	  FCA	   Chronic	  relapsing	  course	  
without	  recovery	  
[53]	  
EAE	   MOG35-­‐55+Pertussis	  
Toxin+	  Quil	  Adjuvant	  
Relapsing	  remitting	  
(demyelination/remyelination)	  




TMEV	   Either	  Monophasic	  stage	  
(relapsing	  for	  seven	  days	  and	  
recover	  within	  three	  weeks)	  or	  





Cuprizone	   Acute	  or	  chronic	  
demyelination	  during	  a	  










In	  pre-­‐	   and	   post-­‐contrast	  T1	  WI,	  MS	   plaques	   appear	   hypointense;	   such	   observations	   have	   been	  
correlated	  with	  both	  demyelination	  and	  axonal	  loss	  [15].	  Post-­‐contrast	  T1	  WI	  provides	  the	  benefit	  
of	  measuring	  blood	  brain	  barrier	  (BBB)	  permeability,	  where	  leakage	  has	  been	  linked	  to	  MS	  lesions	  
and	   the	   progression	   of	   relapsing	   symptoms	   [85].	   In	   MRI	   studies	   of	   MS	   animal	   models,	   similar	  
approaches	   have	   been	   used,	   including	   2D/3D	   pre-­‐	   and	   post-­‐contrast	   T1	   WI	   and	   T2	   WI.	   These	  
techniques	  are	  often	  used	   in	  addition	  to	  diffusion	  tensor	   imaging	  (DTI)	  parameters	   (explained	   in	  
Section	   3.3),	   such	   as	   fractional	   anisotropy	   (FA),	   relative	   anisotropy	   (RA),	   axial	   and	   radial	  
diffusivities	  (AD,	  RD)	  [42,	  43].	  	  
T1	  WI	  has	  been	  shown	  to	  be	  sensitive	  to	  chronic	  progression	  in	  the	  TMEV	  MS	  mouse	  model	  using	  
normal	  C57BL6	  mice	  and	   immune	  differentiation	  marker-­‐deficient	  mice	   [80].	   In	   this	  experiment,	  
TMEV	  was	  administered	  to	  four	  groups	  of	  mice,	  viz:	  (1)	  normal	  C57BL6	  mice,	  as	  a	  reference	  of	  T1	  
hypointensity	   lesion	   load;	   (2)	   immuno-­‐deficient	   C57BL6	   mice	   RAG	   (Recombination	   activation	  
gene)-­‐1	  deficient;	  (3)	  RAG-­‐1	  deficient	  mice	  with	  CD4+;	  and	  (4)	  RAG-­‐1	  deficient	  mice	  with	  CD8+	  T-­‐
cells.	  T1	  WI	  was	  performed	  at	  7	  T	  to	  study	  MS	  lesions.	  In	  control	  C57BL6	  mice,	  hypointense	  regions	  
were	  mostly	   located	   in	   the	  periventricular	   area	   and	  hippocampus	   (Figure	   2).	   In	   RAG-­‐1	  deficient	  
mice,	  there	  was	  a	  significant	  reduction	  in	  the	  T1	  hypointensity	  lesion	  load	  compared	  with	  C57BL6	  
TMEV	  mice,	   indicating	   the	   importance	  of	   the	   innate	   immune	   system	   for	  disease	  progression.	  T1	  
hypointense	   lesions	   increased	   in	  RAG-­‐1	  mice	  administered	  CD8+	  T-­‐cells,	   but	  were	  unaffected	   in	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RAG-­‐1	  mice	   administered	  CD4+	  T-­‐cells	   [77].	   This	   study	  highlights	   the	  distinctive	   role	  of	   CD4	  +	   T	  
cells	  (or	  T	  helper	  cells),	  which	  play	  a	  major	  role	  in	  the	  EAE	  model	  [64,	  86];	  compared	  with	  the	  role	  
of	  CD8+	  cells	  in	  the	  TMEV	  mouse	  model	  of	  MS.	  It	  has	  been	  suggested	  that	  these	  differences	  may	  
have	  contributed	  to	  the	   lack	  of	  success	  of	   treatments	  targeting	  CD4+	  T	  cells	   in	  the	  treatment	  of	  
human	  MS	  [80].	  
	  
Figure	  2.	  3D	  T1	  weighted	   imaging	  at	  7T	  of	  C57BL6	   infected	  with	  TMEV	   (A),	   (B)	  coronal	  and	   (C)	  axial	   sections	  were	  
extracted	  from	  3D	  T1	  WI.	  7	  days	  post	   infection.	  T1	  hypointense	   lesions	  were	  more	  pronounced	   in	  the	  periventricular	  
area	   and	   adjacent	   to	   the	   hippocampus	   as	   indicated	   by	   the	   white	   frames.	   (TR/TE=	   200/10	   ms,	   voxel	   dimensions=	  
135×200×200	  μm)	  [80].	  	  	  
T2-­‐weighted	  imaging	  
T2	  WI	  plays	  a	  major	  role	   in	  the	  detection	  of	  an	  MS	  lesion.	  The	  detection	  of	  new	  T2	  hyperintense	  
lesions	   after	   the	   onset	   of	   the	   first	   MS	   attack	   signifies	   further	   progression	   of	   the	   disease,	   and	  
indicates	   the	  beginning	  of	   the	   relapsing	   remitting	  disease	  course	   [83,	  84].	  High	   resolution	  T2	  WI	  
has	  also	  been	  used	  to	  detect	  brain	  atrophy	  in	  patients	  with	  MS	  [87-­‐89].	  	  
High	  resolution	  T2	  WI	  has	  been	  shown	  to	  be	  useful	  for	  measurement	  of	  volumetric	  changes	  in	  EAE	  
mouse	  brains	   that	  were	   significantly	   correlated	  with	  histopathological	   analysis	   [78].	   This	  ex-­‐vivo	  
MRI	   study	   in	   EAE-­‐mice	   found	   significant	   reductions	   in	   the	   volume	  of	   the	   cerebellum,	   cerebellar	  
cortex	   and	   molecular	   layer	   of	   the	   cerebellar	   cortex.	   Atrophy	   in	   the	   molecular	   layer	   of	   the	  
cerebellar	   cortex	   is	   related	   to	   loss	   of	   Purkinje	   cells	   [90].	   Such	   detection	   of	   grey	   matter	   (GM)	  
atrophy	   was	   important	   as	   it	   was	   strongly	   correlated	   with	   progressive	   development	   of	   clinical	  
disability	  [78,	  91].	  
A	  more	  recent	  T2	  WI	  in	  vivo	  study	  in	  EAE-­‐mice	  from	  the	  same	  group	  [32]	  re-­‐affirmed	  the	  presence	  
of	   GM	   atrophy	   in	   the	   cerebral	   cortex,	   characterized	   by	   a	  major	   decrease	   in	   the	   volume	   of	   the	  
cerebellum	   by	   80	   days	   post-­‐EAE	   induction	   [31].	   However,	   there	  was	   no	   discernable	   correlation	  
between	   disease	   severity	   and	   whole	   brain	   volume,	   or	   volume	   changes	   in	   the	   cerebral	   cortices	  
during	   the	   course	   of	   the	   disease.	   Nevertheless,	   in	   vivo	   mouse	   MRI	   studies	   are	   advantageous	  
compared	  with	  ex-­‐vivo	  studies,	  as	  there	  is	  less	  distortion	  of	  the	  anatomical	  structures	  that	  occurs	  
in	  ex	  vivo	  studies	  due	  to	  the	  brain	  tissue	  fixation	  process	  [31].	  As	  additionally,	  in	  vivo	  longitudinal	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studies	   facilitate	  measurement	  of	   temporal	  volumetric	  changes	  from	  the	  data	  acquired	  pre-­‐	  and	  
post	  induction	  of	  the	  disease	  and	  during	  the	  disease	  course	  [92].	  	  
In	  the	  TMEV	  mouse	  model	  of	  MS	  induced	  using	  SJL/J	  mice,	  T2	  WI	  showed	  a	  correlation	  between	  
the	   presence	   of	   deep	   grey	   matter	   hypointense	   lesions	   and	   functional	   impairments	   [93].	   T2	  WI	  
hypointense	   signals	   have	   been	   observed	   in	   several	   deep	   grey	   matter	   structures,	   including	   the	  
thalamus,	  caudate,	  putamen	  and	  dentate	  nuclei	   (Figure	  3),	  and	  these	  have	  been	  correlated	  with	  
cognitive,	   neuropsychiatric	   and	   motor	   dysfunctions	   [89].	   Additionally,	   TMEV	   SJL/J	   mice	  
experienced	  severe	  disability	  that	  was	  correlated	  with	  the	  gradual	  development	  of	  a	  thalamic	  T2	  
hypointensity	  [93].	  	  
	  
Figure	   3.	   The	   correlation	   between	   increasing	   hypointensity	   of	   the	  medio-­‐dorsal	   thalamic	   nucleus	   on	   T2-­‐weighted	  
images	  and	  disease	  progression	  (A)	  One	  month	  post	  disease	  induction,	  (B)	  4	  months,	  (C)	  6	  months	  and	  (D)	  12	  months	  
as	  indicated	  by	  red	  arrows.	  3D	  volume	  RARE	  sequence	  at	  7T	  with	  TR=1500	  ms,	  TE=70	  ms,	  ETL=16,	  FOV=3.20×1.92×1.92	  
cm,	  voxel	  dimensions=	  125×150×150	  μm	  [93].	  	  	  	  	  
T2	   hypointensity	  may	   be	   caused	   by	   several	   factors	   including	   iron,	   free	   radicals,	   the	   presence	   of	  
macrophages	   and	   deoxyhemoglobin	   [94].	  T2	   hypointensity	   has	   been	   reported	   in	   human	   studies	  
[95,	  96],	  but	  as	   the	   lesions	  were	   located	  within	   the	  deep	  grey	  matter,	  biopsies	  were	  difficult	   to	  
perform	  to	  investigate	  the	  tissue	  properties	  [94].	  In	  a	  MS	  study	  in	  humans	  at	  3	  T	  [97],	  there	  was	  a	  
correlation	   between	   the	   physical	   changes	   assessed	   using	   the	   Expanded	   Disability	   Status	   Scale	  
(EDSS)	  and	  alterations	  of	  signal	  intensities	  in	  the	  globus	  pallidus	  and	  caudate	  nucleus	  [90].	  	  
In	  other	  work,	  an	  excessive	  grey	  iron	  deposition,	  assessed	  by	  T2	  hypointensity	  within	  the	  deep	  grey	  
matter	   structures	   [98],	   was	   correlated	   with	   cognitive	   dysfunction.	   On	   the	   other	   hand,	   T2	  
hyperintensity	  may	  serve	  as	  a	  potential	  biomarker	  for	  detecting	  active	  MS	  lesions	  [13].	  However	  it	  
exhibits	   low	   specificity	   to	   acute	   and	   chronic	  MS	   disease	   pathology	   [99-­‐101].	   This	   is	   due	   to	   the	  
presence	   of	   inflammation,	   edema	   and	   demyelination	   in	   acute	   lesions,	   and	   profound	  
demyelination,	  axonal	  loss	  and	  gliosis	  in	  chronic	  lesions	  [13].	  These	  pathologies	  could	  result	  in	  the	  




Correlation	  of	  T1	  and	  T2	  weighted	  signal	  intensity	  changes	  with	  histopathology	  requires	  an	  animal	  
model	   that	   can	   produce	   a	   large	   number	   of	   inflammatory	   lesions	   [81,	   103].	   This	   has	   been	  
established	   in	   the	  clonal	  adaptive	   transfer	  EAE	  model	  using	  SJL/J	  mice.	  3D	  high	  resolution	  T1	  WI	  
and	  T2	  WI	  at	  2.35T	  were	  acquired	  to	  trace	  the	   lesion	  formation	  [104].	  During	  the	  acute	  stage	  (9	  
days	  post	  adaptive	  transfer),	  two	  independent	  patterns	  of	  lesions	  were	  detected:	  (1)	  hypointense	  
lesions	  on	  both	  T1	  and	  T2	  WI	  (Type	  A	  lesions),	  (2)	  other	  lesions,	  characterized	  by	  hypointensity	  on	  
T1	   WI	   and	   hyperintensity	   on	   T2	   WI	   (Type	   B	   lesions).	   The	   histology	   studies	   using	   Mac-­‐3	  
immunostaining	  and	  haematoxylin	  staining	  show	  that	  type	  A	  lesions	  contained	  a	  higher	  density	  of	  
inflammatory	  cells	  and	  myelin	   loss	  and	  were	  more	  destructive	  than	  type	  B	   lesions	  [104].	  On	  the	  
other	  hand,	  for	  B	  type	  lesions,	  T2	  hyperintensity	  was	  postively	  correlated	  with	  density	  of	  activated	  
microglia	   and	   reactive	   astrocytes,	   although,	   T1	   hypointensity	   was	   negatively	   correlated	   [104].	  
Serial	   MRI	   was	   performed	   during	   the	   disease	   cycle,	   and	   the	   patterns	   of	   two	   lesions	   were	  
heterogeneous	  [104].	  At	  the	  end	  of	  the	  disease	  cycle	  (30	  days	  post	  adaptive	  transfer),	  for	  type	  A	  
lesions,	   T1	   hypointensity	   persisted	   and	   T2	   hypointensity	   diminished.	   For	   type	   B	   lesions,	   T1	  
hypointensity	  diminished	  and	  T2	  hyperintensity	  persisted	  [104].	  	  
Inversion	  recovery	  
DIR	   and	   FLAIR	   imaging	   can	   increase	   the	   sensitivity	   of	   detecting	   focal	   areas	   of	   hyperintensity,	  
especially	   in	   grey	   matter	   and	   cortical	   lesions	   [105,	   106].	   However,	   these	   techniques	   have	   low	  
sensitivity	   for	   the	   heterogeneous	   pathologic	   substrate	   of	   individual	   lesions.	   Although	   a	   recent	  
study	  [107]	  compared	  T1	  WI,	  T2	  WI	  and	  FLAIR	  at	  both	  3T	  and	  7T,	  these	  techniques	  did	  not	  appear	  
to	   increase	  sensitivity	   for	  detection	  of	  WM	   lesions.	  On	   the	  other	  hand,	  3D-­‐FLAIR	  at	  7T	  could	  be	  
tailored	   to	   improve	   sensitivity	   in	   depicting	   grey	  matter	   lesions	   [107].	   This	   technique	   combined	  
axial	   FLAIR	   (1mm3	   isotropic	   resolution)	   and	   T2*	  WI	   (0.55mm3	   isotropic	   resolution),	   to	   produce	  
FLAIR*	   with	   0.55	   mm3	   isotropic	   resolution	   [106].	   The	   resulting	   image	   showed	   suppression	   of	  
cerebrospinal	   fluid	   (CSF)	   and	   high-­‐resolution	   visualization	   of	   microvascular	   structures,	   which	  
enabled	  investigation	  of	  the	  presence	  of	  interlesional	  veins	  in	  WM	  lesions	  [106].	  Such	  lesions	  were	  
detected	   in	   the	   pons	   and	   cerebellum	   and	   could	   be	   related	   to	   the	   presence	   of	   iron-­‐containing	  
macrophages	  [106].	  	  	  	  	  	  
In	  rodent	  brain	  MRI,	  inversion	  recovery	  was	  used	  to	  produce	  stronger	  T1-­‐weighting.	  For	  example,	  a	  
T1	   weighted	   3D	  Modified	   Driven	   Equilibrium	   Fourier	   Transformation	   (MDEFT)	   sequence	   at	   9.4T	  
[108]	   has	  been	  used	   to	   enhance	   visualisation	  of	   cortical	   areas,	   the	   striatum	  and	   the	   ventricular	  
system.	  However,	  T1	  WI	  MDEFT	  could	  not	  detect	  EAE	  inflammatory	  lesions,	   in	  contrast	  to	  T2	  and	  
T2*	  WI	  [108].	  FLAIR	  with	  inversion	  recovery	  does	  not	  appear	  to	  have	  been	  applied	  to	  the	  study	  of	  
rodent	   models	   of	   MS,	   as	   the	   T1	   relaxation	   time	   is	   considerably	   long	   in	   high	   magnetic	   fields	  
commonly	  used	  in	  these	  studies	  [81].	  	  
Limitation	  of	  conventional	  MRI	  in	  rodent	  models	  of	  MS	  
The	  limitations	  of	  conventional	  MRI	  techniques	  to	  monitor	  or	  assess	  the	  contents	  of	  the	  MS	  lesion	  
are	   caused	   by	   the	   heterogeneity	   of	   MS	   lesions,	   comprising	   cellular	   debris	   from	   demyelination	  
and/or	   remyelination	  processes,	  permanent	  axonal	   loss	  and	  cellular	  activity	   [27].	   In	  addition,	  T1-­‐	  
and	   T2-­‐weighted-­‐imaging	   cannot	   detect	   MS	   lesions	   within	   normal-­‐appearing	   white	   matter	  




Cryogenic	  radiofrequency	  coil	  mouse	  brain	  MRI	  
The	  recent	  introduction	  of	  cryogenic	  radio	  frequency	  (RF)	  coils	  (cryocoil)	  may	  improve	  the	  role	  of	  
conventional	  micro	  MRI	   in	   assessing	   pathological	   changes	   in	   rodent	  models.	   At	   9.4T,	   cryogenic	  
coils	  boost	  Signal	  to	  Noise	  Ratio	  (SNR)	  by	  a	  factor	  of	  up	  to	  2.9,	  which	  can	  be	  exploited	  for	  in-­‐vivo	  
imaging	  to	  significantly	  shorten	  experiment	  time	  [111,	  112].	  For	  example,	  a	  volumetric	  T2	  WI	  at	  (60	  
μm)3-­‐	   isotropic	   resolution	   could	   be	   acquired	  within	   45	  min.	   The	   cryocoil	   has	   a	  maximum	   signal	  
penetration	  of	  approximately	  3	  mm	  from	  the	  brain	   surface	  and	  can	   reveal	   intricate	  cortical	  and	  
subcortical	   details	   of	   the	  mouse	   brain	   [112].	   Despite	   its	   high	   sensitivity,	   the	   cryocoil	   has	   some	  
disadvantages	  in	  terms	  of	  its	  inhomogeneous	  RF	  excitation	  profile.	  Gradual	  loss	  of	  signal-­‐to-­‐noise	  
ratio	  for	  deeper	  (ventral)	  brain	  structures	  were	  also	  observed	  due	  to	  the	  positioning	  of	  the	  surface	  
array	  coil	  on	  the	  cortex.	  However,	  such	  artifacts	  can	  be	  minimized	  with	  careful	  adjustment	  of	  the	  
RF	  power	  and	  image	  post-­‐processing	  [111,	  112].	  	  
In-­‐vivo	  conventional	  micro	  MRI	  using	  the	  cryogenic	  RF	  coil	   (T1,	  T2	  and	  T2*	  weighted	   imaging)	  has	  
been	  used	  to	  detect	  MS	  lesions	  prior	  to	  the	  appearance	  of	  the	  symptoms	  in	  EAE-­‐mice	  immunized	  
with	   PLP139-­‐151,	   complete	   Freud’s	   adjuvant	   (CFA)	   and	   heat-­‐killed	   mycobacterium	   [108].	   High-­‐
resolution	   images	   were	   used	   to	   detect	   MS	   lesions	   before	   the	   disease	   manifestations	   in	   the	  
cerebellum,	  cerebral	  cortex	  and	  subcortical	  region	  (figure	  4)	  [108].	  	  
3.2. Contrast agent enhancement and cellular tracking 
Paramagnetic	   gadolinium	   (Gd)	   contrast	   agents	   are	   commonly	   used	   to	   investigate	  MS.	   Recently	  
developed	  contrast	  agents	  such	  as	  ultra-­‐small	  and	  small	  superparamagnetic	  iron	  oxide	  (USPIO	  and	  
SPIO	   particles,	   respectively)	   [15]	   have	   been	   used	   to	   monitor	   the	   cellular	   mechanisms	   of	   MS	  
inflammation.	  The	  cells	  of	  the	  monocyte-­‐macrophage	  system	  take	  up	  the	  iron	  oxide	  particles	  and	  
their	   infiltration	   into	   the	   lesion	   sites	   could	   be	   detected	   using	  MRI	   [113].	   The	  major	   differences	  
between	   USPIOs	   and	   Gd	   are	   their	   pattern	   of	   enhancements.	   Gadolinium	   enhancement	   reflects	  
leakage	   of	   the	   blood	   brain	   barrier	   (BBB)	  whereas	   the	  USPIOs’	   enhancements	   represent	   cellular	  
infiltration	   [34,	  114-­‐116].	   Several	   studies	   [115,	  117,	  118]	  have	   shown	   that	   the	  USPIO	  pattern	  of	  
enhancements	  is	  correlated	  with	  MS	  disability,	  axonal	  loss	  and	  patient’s	  response	  to	  treatment.	  	  
The	  biological	  specificity	  of	  the	  USPIO	  depends	  upon	  the	  molecular	  characteristics	  of	  the	  applied	  
particles	   [34,	  114].	  For	  example,	  USPIO	  particles	  SHU555C	  and	  Ferumoxtran-­‐10	  differ	   in	   size	   (25	  
nm	  vs.	  30nm),	  and	  body	  circulation	  half-­‐life	   (6-­‐8	  h	  vs.	  24-­‐30	  h).	   In-­‐vitro,	   the	  negative	  charge	  on	  
SHU555C	  particles	  produced	  preferential	  uptake	  by	  activated	  monocytes	  [119].	  	  
There	   is	   still	   controversy	   as	   to	   whether	   Gd	   or	   USPIO	   provides	   a	   better	   early	   indication	   of	   MS	  
pathology	  [34,	  114,	  115].	   In	  some	  cases,	  USPIO	  is	  superior	  to	  Gd,	  because	  it	  can	  detect	   lesions	  a	  
few	  weeks	  earlier	  than	  Gd	  enhancement	  [34].	  USPIO	  lesion	  enhancement	  may	  persist	  longer	  after	  
Gd	  enhancement	  has	  ceased	  and	  show	  spatial	  distribution	  of	  the	  immune-­‐reactive	  cells	  post	  BBB	  
repair	  [34,	  82].	  A	  recent	  comparison	  between	  USPIO	  and	  Gd	  enhancements	  in	  10	  patients	  with	  RR-­‐
MS	  [120]	  showed	  that	  the	  same	  lesions	  were	  seen	  with	  both	  contrast	  agents,	  but	  that	  additional	  





Figure	   4.	   Application	   of	   micro	   MRI	   T2	   WI	   in	   assessing	   evolution	   of	   the	   lesion	   prior	   and	   during	   disease	   onset	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(A)	  Detection	  of	  MS	  lesions	  in	  subcortical	  region,	  cerebellum	  and	  cerebral	  cortex	  in	  seven	  EAE-­‐mice	  prior	  to	  the	  disease	  
onset	  until	  the	  disease	  starting	  time.	  (B)	  T2	  weighted	  images	  from	  day	  14	  (d-­‐14)	  prior	  to	  disease	  manifestation	  until	  the	  
first	  day	  when	  symptoms	  were	  initiated	  (d0)[108].	  
Post-­‐contrast	   studies	   have	   been	   used	   to	   monitor	   BBB	   permeability,	   which	   could	   be	   disrupted	  
during	  deposition	  of	  new	  MS	  lesions	  [33,	  121].	  To	  assess	  the	  development	  dynamics	  of	  MS	  lesions,	  
the	   TMEV	   mouse	   model	   of	   MS	   has	   been	   induced	   in	   interferon-­‐gamma	   receptor	   knockout	  
mice[33].	  In	  TMEV	  mice,	  there	  was	  acute	  progressive	  demyelination	  without	  remission	  resulting	  in	  
extensive	   brain	   and	   brainstem	   lesions	   [33].	   This	   model	   has	   allowed	   a	   comprehensive	  
understanding	  of	  the	  T2	  lesion	  load	  and	  enhanced	  lesions.	  One	  study	  [33]	  has	  explored	  four	  unique	  
patterns	  of	  T2	  lesions,	  including	  expanding,	  expanding	  retracting,	  fluctuating	  and	  stable	  (Figure	  5).	  
As	  this	  model	  produces	  extensive	  MS	  lesions,	  the	  T2	  WI	  detects	  more	  MS	  lesions	  compared	  with	  
post-­‐contrast	   enhanced	   imaging,	   and	   with	   earlier	   temporal	   sensitivity	   compared	   with	   Gd	  
enhancement	  [33].	  	  
Predicting	   disease	   severity	   in	   MS	   is	   a	   critical	   issue	   for	   planning	   approaches	   to	   treatment	   and	  
consequently	   limiting	   development	   of	   neurological	   disability	   [13].	   USPIO	   has	   been	   used	   as	  
indicator	  of	  disease	  progression	   in	  rats	  with	  RR	  EAE	  [117].	  Rats	  with	  positive	  detection	  of	  USPIO	  
particles	  (+USPIO	  rats)	  show	  significant	  tissue	  alteration	  at	  the	  first	  attack	  and	  more	  severe	  clinical	  
signs	  compared	  to	   -­‐USPIO	  rats	  during	   the	  second	  attack	   (Figure	  6).	  This	   study	  demonstrates	   the	  




Figure	   5.	   Characterisation	   of	   lesion	   developments	   in	   interferon-­‐gamma	   receptor	   knockout	   mice	   3D	   volume	  
rendering	  resampled	  from	  T2	  WI	  3D	  datasets	  of	  the	  examined	  mice.	  3D	  RARE	  acquired	  at	  7T	  (TR=1500	  ms,	  TE=70	  ms,	  
ETL=16,	  FOV=3.5×3.5×3.5	  cm	  voxel	  dimensions	  218	  ×	  218	  ×	  218	  μm)	  [33].	  
	  
	  
Figure	   6.	   Detection	   of	   macrophages	   using	   USPIO	   contrast	   agent	   at	   1.5T	   for	   assessment	   of	   their	   role	   in	   the	  
development	   of	   secondary	   progressive	   EAE	   in	   rats	   (A)	   Sagittal	   T1	  WI	   and	   (B)	   axial	   T1	  WI	   show	   hyperintensity	   and	  
reflects	   the	  uptake	  of	  USPIO	   in	   the	  CNS.	   (C)	  Axial	  T2	  WI	   shows	  hypointensity	  as	   in	   indicated	  by	  arrows.	  These	  signal	  




3.3. Diffusion Weighted Imaging (DWI) and Tractography     
Diffusion	  tensor	  imaging	  
The	  measurement	  of	  tissue	  molecular	  diffusion	  using	  diffusion	  weighted	   imaging	  (DWI)	   is	  widely	  
used	  in	  MS	  research	  [122-­‐124].	  MRI	  is	  sensitized	  to	  microscopic	  diffusion	  of	  water	  in	  tissue	  by	  the	  
application	   of	   diffusion	   gradients.	   Gaussian	   modelling	   of	   tissue	   water	   diffusion	   can	   broadly	   be	  
classified	   as	   non-­‐restricted	   (isotropic)	   and	   directionally	   restricted	   (anisotropic)	   diffusion.	   In	  
neuronal	   tissues,	   isotropic	   diffusion	   can	   be	   identified	   within	   cerebrospinal	   fluid	   (CSF)	   and	   to	   a	  
lesser	  extent	  the	  GM,	  whereas	  anisotropic	  diffusion	  has	  often	  been	  correlated	  with	  the	  degree	  of	  
myelination	  and	  axonal	  fibre	  directionality	  of	  the	  WM	  [125,	  126].	  	  
The	  directionality	  and	  strength	  of	  anisotropic	  diffusion	  can	  generally	  be	  described	  as	  an	  ellipsoid	  
diffusion	  tensor,	  which	  can	  be	  measured	  using	  magnetic	  resonance	  diffusion	  tensor	  imaging	  (DTI)	  
[125,	   126].	   DTI	   acquisition	   requires	   a	   minimum	   of	   six	   orthogonally	   encoded	   DWI	   and	   one	  
unweighted	  image	  [127,	  128].	  From	  these	  measurements,	  three	  eigenvectors	  (ν1,	  ν2,	  ν3)	  and	  their	  
rotational	   invariant	   eigenvalues	   (λ1,	  λ2,	  λ3)	   can	   be	   derived	   to	   describe	   the	   diffusion	   tensor	  
[128].	   The	   largest	   eigenvector	   (ν1),	   the	   direction	   of	   the	   major	   diffusion	   component,	   and	   its	  
associated	   eigenvalue	   (λ1)	   represent	   the	  magnitude	   of	   axial	   diffusivity	   along	   the	   length	   of	   the	  
axonal	  fibre	  bundle	  [129].	  ν2,λ2	  and	  ν3,λ3	  describe	  transverse	  diffusion	  components	  orthogonal	  
to	  the	  fiber	  bundle,	  where	  the	  average	  of	  λ2	  and	  λ3	  is	  known	  as	  radial	  diffusivity	  (Figure	  7)	  [127,	  
129,	  130].	  	  
DTI	  parameters	  can	  be	  used	  to	  derive	  rotational	  invariant	  diffusion	  metrics:	  mean	  diffusivity	  (MD),	  
Fractional	  Anisotropy	   (FA)	  and	  Rational	  Anisotropy	   (RA).	  MD	  describes	   the	  average	  of	  diffusivity	  
components	  within	  each	  voxel	  [131].	  The	  diffusion	  tensor	  parametric	  FA	  is	  more	  commonly	  used	  
than	   RA	   in	   the	  DTI	   literature	   [132].	   FA	   values	   range	   from	   0	   to	   1	   to	   describe	   the	   degree	   of	   the	  
anisotropy	  of	   the	   intra-­‐voxel	  diffusivity	   [133].	  FA	  values	   in	  WM	  are	  generally	  higher	   than	   in	  GM	  
due	  to	  increased	  diffusion	  directionality	  of	  the	  myelin	  axon	  bundles	  [128].	  	  	  
DTI	  parameter	  changes	  in	  MS	  	  
DTI	   derived	   parameters	   are	   powerful	   and	   sensitive	   measures	   for	   assessing	   MS	   pathological	  
changes.	  MS	  pathology	  is	  associated	  with	  damage	  to	  the	  white	  matter	  myelin	  structure,	  resulting	  
in	  disruption	  of	  molecular	  water	  diffusion	  and	  a	   consequential	   reduction	   in	  diffusion	  anisotropy	  
[13].	  A	  summary	  of	  DTI	  parametric	  changes	  in	  WM	  affected	  by	  MS	  is	  illustrated	  in	  Figure	  7.	  	  
DTI	  parametric	  maps	  provide	  distinguishing	  characteristics	  for	  careful	  interpretation	  of	  MS	  lesions,	  
even	   for	   those	   that	   are	   readily	   detectable	   by	   the	   conventional	   imaging	   techniques	   [123].	   MS	  
lesions	   are	  heterogeneous	  with	   transient	   lesions	  due	   to	  oedema,	   areas	  with	  demyelination	   and	  
remyelination,	  and	  areas	  with	  advanced	  neurodegeneration	  [82,	  134].	  	  
Compared	  with	  the	  normally-­‐appearing	  white	  matter	  (NAWM),	  MS	  focal	  lesions	  showed	  increased	  
MD	   which	   indicated	   some	   loss	   of	   the	   structural	   barrier	   to	   water	   molecular	   diffusion	   and	   a	  
decrease	   in	  FA	  due	   to	  disorganisation	  of	  WM	  structures	   [122].	  Co-­‐localisation	  of	  T1	  hypointense	  
and	  DTI	   lesions	  may	  signify	  areas	  suffering	  from	  irreversible	  tissue	  damage	  [135].	  Additionally,	  a	  
longitudinal	  progressive	  MS	  study	   [136]	   showed	   that	  worsening	   lesions	  could	  be	  detected	  more	  
sensitively	   as	   areas	   with	   increasing	   MD,	   which	   were	   otherwise	   indistinguishable	   using	   post-­‐
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contrast	  T1	  WI.	  On	  the	  other	  hand,	   lesion	  areas	  with	   increased	  T2	   relaxation	   time	  and	   increased	  
MD	  appear	  to	  reflect	  a	  decrease	  in	  the	  axonal	  myelin	  (intracellular)	  water	  content	  and	  an	  increase	  
in	  the	  extracellular	  water	  due	  to	  tissue	  damage	  [137]	  
	  
Figure	  7.	  The	  relationship	  between	  the	  white	  matter	  axonal	  fibres,	  myelin	  structure	  and	  DTI	  derived	  parameters	  in	  
MS	  pathology.	  The	  demyelination,	  axonal	  injury	  and	  inflammation	  processes	  in	  MS	  typically	  result	  in	  a	  decrease	  of	  FA,	  
and	  AD	  and	  an	  increase	  in	  RD.	  	  
DTI	  studies	  of	  MS	  animal	  models	  	  
AD	  and	  RD	  measurements	  are	  potentially	  more	  sensitive	  than	  MD	  in	  diagnosis	  of	  MS	  lessions	  due	  
to	  characteristic	  high	  diffusion	  anisotropy	  in	  the	  WM	  [132,	  138].	  In	  MS	  studies	  using	  the	  cuprizone	  
rodent	   model	   [139,	   140],	   decreasing	   AD	   and	   increasing	   RD	   were	   robust	   surrogate	  markers	   for	  
axonal	   damage	   and	  demyelination,	   respectively.	   These	   conditions	  were	   observed	   in	   various	  DTI	  
MRI	  animal	  studies,	   for	  example:	   (i)	   In	  a	  retinal	   ischemia	  mouse	  model,	  where	  a	  decrease	  of	  AD	  
correlated	  with	  axonal	  injury	  [141].	  (ii)	  In	  a	  spinal	  DTI	  study	  of	  a	  mouse	  model	  of	  chronic	  EAE	  [142],	  
histology	  data	  confirmed	  a	  correlation	  of	  intense	  anti-­‐β-­‐amyloid	  precursor	  protein	  staining	  with	  	  
a	   decrease	   in	   AD	   associated	   with	   axonal	   damage;	   and	   an	   increase	   in	   radial	   diffusivity	   with	  
diminished	   luxol	   fast	   blue	   (LFB)	   staining	   as	   a	   biomarker	   of	   demyelination	   (iii)	   In	   a	   cuprizone-­‐
induced	  demyelination/remyelination	  mouse	  model	  [143],	  T2	  hyperintensity,	  a	  reduction	  in	  AD	  and	  
an	   increase	   in	  RD	  were	  specifically	  observed	   in	   the	  caudal	   segment	  of	   the	  corpus	  callosum,	  and	  
these	  were	  correlated	  with	  histological	  observations	  of	  demyelination	  (LFB	  staining),	  axonal	  injury	  
(neurofilaments	   staining),	   microglial	   accumulation	   and	   cellular	   infiltration.	   (iv)	   In	   inflammatory	  
optic	   neuritis	   (ON)	   in	   an	   EAE	   mouse	   model	   [144,	   145],	   uniform	   ON	   resulted	   in	   axonal	   injury	  





Figure	  8.	  Assessment	  of	  optic	  nerve	  degeneration	   in	  EAE-­‐mice	  using	  DTI	   indices.	  A	  reduction	   in	   relative	  anisotropy	  
(RA)	  value	  can	  be	  observed	  in	  the	  EAE	  mouse	  (b)	  compared	  with	  the	  control	  subject	  (a).	  Axial	  diffusivity	  decreases	  and	  
radial	  diffusivity	  increases	  in	  the	  EAE	  mouse	  (d,	  f,	  respectively),	  in	  comparison	  with	  the	  control	  (c,	  e,	  respectively).	  DTI	  
was	  acquired	  using	  Stejskal-­‐Tanner	  sequence	  at	  4.7T,	  TR=1.7	  second,	  TE=50	  ms,	  6	  diffusion	  directions	  acquired	  with	  b-­‐
value=838	  s/mm2,	  NEX=4,	  slice	  thickness=0.5	  mm,	  FOV=3×3	  cm,	  and	  resolution=59	  ×	  59	  ×	  500	  μm	  [77].	  
A	  recent	  study	   [146]	  has	  assessed	  the	  axial	  and	  radial	  diffusivities	  within	   the	  abnormally	   low	  FA	  
areas	   in	   the	   brains	   of	   patients	   with	   MS.	   The	   brain	   regions	   examined	   include	   fornices,	   inferior	  
longitudinal	  fasciculus,	  optic	  radiations,	  and	  parts	  of	  the	  corpus	  callosum.	  There	  was	  an	  increase	  in	  
RD	   caused	   by	   demyelination	   but	   surprisingly,	   there	   was	   only	   a	   small	   increase	   in	   AD	   [146].	   	   A	  
complicated	  pattern	  of	  change	  in	  diffusivities	  may	  occur	  due	  to	  axonal	  loss	  [147]	  or	  an	  increase	  in	  
axonal	  diameter.	  This	  was	  supported	  by	  previous	  findings	  in	  post-­‐mortem	  MS	  spinal	  cord	  studies	  
which	  showed	  areas	  of	  T2	  WI	  hyperintensities	  [148].	  For	  areas	  containing	  crossing	  fibers,	  abnormal	  
changes	   to	   the	   FA,	   AD	   and	   RD	  must	   be	   carefully	   assessed	   as	  MS	   pathology	   in	   these	   areas	   can	  
produce	  unexpected	  results	  such	  as	  an	  apparent	  increase	  in	  diffusion	  anisotropy	  [133].	  
Investigation	  of	  DTI	  parametric	  changes	   in	  MS	  rodent	  models	  [77,	  142,	  143]	  may	  not	  necessarily	  
reflect	  pathological	  changes	  in	  patients	  with	  MS.	  For	  example	  in	  the	  mouse	  model	  of	  MS,	  changes	  
in	  RD	  were	  not	  observed,	   although	   severe	  demyelination,	   inflamation	  and	  axonal	   damage	  were	  
detected	   by	   histology	   [131].	   Such	   negative	   observations	   may	   be	   due	   to	   confounding	   factors	  
affecting	   RD	   senstivity	   for	   detection	   of	   demyelination;	   for	   example,	   inflammation	   due	   to	   the	  
presence	  of	  activated	  microglia	  and	  macrophages,	  T	  cell	  infiltration,	  as	  well	  as	  vasogenic	  oedema	  
affect	  the	  apparent	  diffusion	  anisotropy	  in	  MS	  lesions	  [131,	  149].	  	  
Many	  DTI	  studies	  of	  human	  MS	  [110,	  124,	  146,	  150,	  151]	  and	  rodent	  models	  [77,	  143,	  152,	  153]	  
are	   focused	  on	  the	  WM	  structures	  as	   they	  are	  the	  anticipated	  sites	  of	  MS	  pathological	  changes.	  
High	  WM	  anisotropy	  provides	   characteristics	   for	   sensitive	  detection	  of	  MS	  pathological	   changes	  
using	  DTI	  measures	  [110,	  124,	  146,	  150,	  151].	  MS,	  however,	  is	  a	  whole	  brain	  disease	  and	  can	  affect	  
GM	  and	  cortical	  areas	  [85].	  A	  three	  year	   longitudinal	  study	  of	  relapsing	  remitting	  MS	  patients	  at	  
1.5T	  has	  reported	  an	  increase	  of	  FA	  in	  normal	  appearing	  grey	  matter	  (NAGM)	  and	  cortical	   lesion	  
volume,	   which	   are	   correlated	   with	   clinical	   disability	   [20].	   This	   unexpected	   finding	   may	   be	  
explained	  by	  crossing	  fibers	   in	  the	  grey	  matter,	  which	  appeared	  to	  have	   low	  FA	  when	  measured	  
using	   DTI	   [20].	   The	   MS	   pathology	   may	   selectively	   reduce	   one	   fibre	   population	   in	   the	   crossing	  
fibres,	  such	  that	  this	  resulted	  in	  an	  apparent	  increase	  in	  FA	  measures	  [133].	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DTI	  Tractography	  studies	  in	  MS	  
DTI	   tractography	  reconstruction	  provides	  a	  unique	  depiction	  of	   three-­‐dimensional	  projections	  of	  
neural	  structures,	  which	  is	  useful	  for	  studying	  brain	  connectivity.	  DTI	  tractography	  can	  potentially	  
be	  used	  to	  stage	  MS	  progression	  as	  MS	  lesions	  produce	  local	  or	  global	  disruptions	  in	  the	  WM	  fibre	  
architecture	   that	   affect	   fibre	   tractography	   profiles	   and	   streamline	   numbers	   [77,	   154].	   DTI	  
tractography	  is	  useful	  for	  extracting	  WM	  pathways	  in	  patients	  with	  MS,	  for	  example,	  in	  the	  corpus	  
callosum,	   for	   investigation	  of	  undetected	  NAWM	  lesions	  and	  consequential	   correlation	  between	  
the	  clinical	  symptoms	  and	  the	  imaging	  findings	  [123,	  150].	  	  
There	   are	   various	  methods	   available	   to	   process	   diffusion-­‐weighted	   imaging	   data	   in	   performing	  
tractography	   [155-­‐157].	   In	   general,	   tractography	   image	   processing	   firstly	   involves	   the	  
determination	  of	  fibre	  orientation	  distribution,	  followed	  by	  the	  propagation	  of	  tracts	  (streamlines)	  
using	  deterministic	  [158]	  and	  probabilistic	  fibre	  tracking	  methods	  [133,	  159].	  Tractography	  can	  be	  
performed	   for	   the	   whole	   brain,	   or	   selectively	   using	   specific	   seeding	   and	   targeted	   regions	   of	  
interest	  [159,	  160].	  	  
DTI	  tractography	  has	  been	  used	  to	  visualize	  the	  effect	  of	  MS	  lesions	  on	  the	  projection,	  association	  
and	  commissural	  fibres	  [150].	  MS	  patients	  exhibited	  an	  increase	  in	  ADC	  and	  reduction	  in	  FA,	  fibre	  
density	  and	  streamline	  profiles	  within	  MS	  lesions	  and	  NAWM	  compared	  with	  healthy	  subjects,	  in	  
which	  measures	  were	   correlated	  with	   the	  pattern	  of	   EDSS	  or	   clinical	   score	  of	  disability.	  Region-­‐
specific	  DTI	  tractography	  has	  also	  demonstrated	  sensitivity	  to	  functional	  changes:	  (i)	  disruption	  of	  
pyramidal	   and	   corticospinal	   tracts	   resulting	   in	   motor	   dysfunction	   [161-­‐163];	   (ii)	   disruption	   of	  
left/right	  thalamic	  connectivity	  affecting	  working	  memory	  in	  early	  MS	  [151].	  	  
Limitations	  of	  DWI	  studies	  in	  animal	  models	  
DWI	  studies	  of	  the	  mouse	  brain,	  either	  ex	  vivo	  [140,	  164,	  165]	  or	  in	  vivo	  [77,	  121,	  143]	  are	  based	  
upon	  FA	  or	  orientation	  colour-­‐coded	  FA	  maps,	  rather	  than	  fibre	  tracking	  [166].	  In	  addition,	  most	  of	  
the	   fibre-­‐tracking	   algorithms	   require	   high	   diffusion	   gradient	   weighting	   (b-­‐values)	   and	   a	   large	  
number	  of	  the	  applied	  diffusion-­‐encoding	  gradients	  directions	  (High	  Angular	  Resolution	  Diffusion	  
Imaging,	  HARDI).	  This	  contributes	  significantly	  to	  the	  experiment	  time,	  and	  can	  be	  problematic	  for	  
in	  vivo	  DWI	  involving	  unhealthy	  participants.	  	  
Ex	  vivo	  HARDI	  could	  be	  a	  reasonable	  solution,	  although	  post-­‐fixation	  procedures	  have	  been	  shown	  
to	  reduce	  the	  diffusivity	  measures	  in	  comparison	  to	  data	  obtained	  from	  in	  vivo	  imaging	  [167,	  168].	  
Such	   affects	   may	   be	   caused	   from	   variable	   tissue	   temperatures,	   microstructure	   properties,	   cell	  
death	  and	  chemical	   fixation	  solution	   [169].	  A	   recent	   study	  examined	   the	  difference	  between	   in-­‐
vivo	   and	  ex-­‐vivo	   DTI	   in	   assessing	   the	   corpus	   callosum	   in	   both	  wild	   type	   C57BL6	   and	   cuprizone-­‐
induced	  mice.	  In	  control	  subjects,	  FA	  measurements	  were	  not	  significantly	  different	  between	  the	  
in	  vivo	  and	  ex	  vivo	  samples;	  however,	  the	  diffusivity	  measurements	  (AD	  and	  RD)	  were	  drastically	  
reduced	   in	   the	   ex-­‐vivo	   experiments	   [153].	   Demyelination	   has	   been	   detected	   in	   the	   corpus	  
callosum	   of	   cuprizone	   mice	   but	   there	   is	   little	   agreement	   between	   in-­‐vivo	   and	   ex-­‐vivo	   FA	  
measurements.	   It	   is	   suggested	   that	   ex	   vivo	   RD	   serves	   as	   a	   potential	   indicator	   of	   demyelination	  
better	  than	  in	  vivo	  RD.	  On	  the	  other	  hand,	  in	  vivo	  AD	  is	  more	  reliable	  than	  ex	  vivo	  AD	  in	  detecting	  
axonal	  injury	  [153].	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The	  primary	  technical	  challenge	  of	  performing	  mouse	  brain	  DWI	  studies	  is	  achieving	  the	  required	  
spatial	   resolution	   while	   preserving	   satisfactory	   signal-­‐to-­‐noise	   ratio	   (SNR).	   This	   is	   especially	  
important	  during	  the	  application	  of	  strong	  diffusion-­‐encoding	  gradients	  which	  results	  in	  significant	  
signal	   attenuation	   and	   lower	   SNR	   [81].	   In	   addition,	   with	   high	   numbers	   of	   sampling	   diffusion-­‐
encoding	   directions,	  DWI	   requires	   a	   longer	   experiment	   time	   compared	  with	   other	   conventional	  
MR	   imaging	   modalities	   [131].	   In	   most	   cases,	   rodent	   DWI	   experiments	   are	   acquired	   at	   high	  
magnetic	  field	  (>7T)	  with	  small	  custom	  coils	  built	  to	  boost	  SNR.	  The	  use	  of	  higher	  magnetic	  fields	  
brings	  undesired	  effects	  such	  as	  higher	  magnetic	  susceptibility	  and	  chemical	  shift	  artefacts,	  longer	  
T1	   and	   shorter	   T2	   relaxation	   times	   [42].	   DWI	   is	   inherently	   sensitive	   to	   motion	   to	   measure	  
microscopic	  water	  displacement;	  and	  therefore,	  voluntary	  and	  involuntary	  movement	  can	  severely	  
affect	  image	  quality	  [129,	  131,	  154].	  The	  use	  of	  respiratory	  gating	  and	  the	  navigator	  sequence	  has	  
been	  developed	  to	  reduce	  these	  artefacts	  [170].	  	  
Assessing	  axonal	  pathology	  has	  become	  an	   integral	  and	  critical	  part	   in	  the	  diagnosis	  of	  MS.	  DW-­‐
MRI	   provides	   unique	   measurements	   of	   the	   distribution	   of	   water	   molecules	   in	   neural	   tissue,	  
especially	  along	  the	  axons	  [171,	  172].	  Recent	  advances	  of	  DWI-­‐MRI	  involves	  development	  of	  axon	  
density	   and	   diameter	   measurements	   in	   the	   white	   matter	   of	   the	   living	   human	   brain,	   which	  
potentially	  bring	  significant	   improvement	  to	  the	  detailed	  characterisation	  of	  MR	  pathology	  [171,	  
173].	  However,	   challenges	   remain	  before	  DWI	  methods	   can	  be	  applied	   in	   clinical	   studies.	   These	  
include	   the	   requirement	   for	   high	   gradient	   amplitude	   (b>3000	   s/mm2),	   relatively	   long	   imaging	  
times	  to	  account	  for	  multiple	  diffusion	  directions	  and	  diffusion	  weightings,	  and	  prior	  knowledge	  of	  
the	  fibre	  orientation	  [173].	  	  
3.4. Magnetization transfer imaging (MTI) 
MTI	   is	   a	   quantitative	   MRI	   technique	   utilising	   the	   interaction	   and	   exchange	   between	   mobile	  
protons	   in	  a	   free	  water	  pool	  and	  bound	  protons	  to	  macromolecules.	  The	  magnetization	  transfer	  
ratio	   (MTR)	   is	  measured	  by	   the	   incorporation	  of	  saturation	  pulses	   into	   the	  preparative	  part	  of	  a	  
gradient	  echo	  or	  a	  spin	  echo	  sequence	  [134,	  174,	  175].	  MTR	  analysis	  can	  be	  done	  through	  a	  whole	  
brain	   voxel	   based	   analysis	   (VBA)	   or	   using	   regions	   of	   interest,	   in	   which	   the	   MTR	   values	   are	  
calculated	   from	   two	   sets	   of	   images	   acquired	   with	   and	   without	   the	   magnetisation	   transfer	  
saturation	   pulses	   [134,	   174,	   175].	   MTI	   allows	   the	   depiction	   of	   several	   diffuse	   occult	   MS	  
pathologies,	  for	  example,	  demyelination,	  gliosis	  and	  inflammation	  [82,	  176].	  
In	   patients	   [177,	   178]	   and	   animal	   models	   [179],	   MS	   pathology	   was	   detected	   by	   an	   abnormal	  
reduction	   in	  MTR,	  which	  was	  suggested	  to	  reflect	  demyelination	  and	  axonal	   loss.	  However,	  MTR	  
determination	   of	   MS	   pathology	   is	   somewhat	   non-­‐specific,	   because	  MTR	   reduction	   can	   also	   be	  
caused	  by	  other	  pathological	  processes,	  such	  as	  oedema,	  gliosis	  and	  inflammation	  [134].	  	  
Several	   groups	   [180-­‐182]	  have	   investigated	  change	   in	  MTR	  and	  correlated	   it	  with	   lesion	  genesis	  
and	   evolution.	   MTR	   reduction	   was	   observed	   a	   few	   months	   preceding	   observable	   Gd	  
enhancement,	  and	  a	  further	  reduction	  in	  MTR	  for	  Gd-­‐enhanced	  lesions	  has	  potential	  to	  highlight	  
deteriorating	   MS	   lesions	   [183,	   184].	   MTR	   can	   be	   combined	   with	   conventional	   MRI	   methods,	  
providing	  additional	  diagnostic	  value	  in	  predicting	  the	  evolution	  of	  T1	  WI	  hypointense	  lesions	  [183,	  
184].	  	  
A	  modest	   reduction	   in	  MTR	   followed	   by	   a	   partial	   or	   complete	   recovery	   of	  MTR	   could	   indicate	  
remyelination	   or	   other	   repair	   mechanisms	   during	   resolution	   of	   inflammation	   or	   gliosis	   [185].	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Abnormal	   changes	   in	   MTR	   were	   also	   sensitive	   or	   detection	   of	   MS	   lesions	   within	   the	   normal	  
appearing	  white	  and	  grey	  matter	   [185].	   In	  other	  work	   [35]	   there	  were	  significant	   fluctuations	   in	  
the	   MTR	   within	   active	   gadolinium-­‐enhanced	   lesions,	   consistent	   with	   the	   demyelination	   and	  
remyelination	  process	  over	  a	  period	  of	  three	  years.	  
In	  a	  comparision	  study	  [30]	  (figure	  9)	  of	  relapsing	  remitting	  MS	  using	  the	  PLP	  (proteolipid	  protein)	  
induced	  mouse	  model	  of	  MS	  and	  a	  chronic	  MOG-­‐induced	  EAE	  mouse	  model	  of	  MS,	  MTR	  histogram	  
analysis	  of	  the	  whole	  brain	  showed	  a	  significant	  reduction	  in	  MTR	  values	  in	  early	  stage	  disease	  (13	  
days	  post	   immunization).	  Using	  VBA,	  MTR	  reduction	  was	  found	  in	  multiple	  brain	  regions	  such	  as	  
the	   corpus	   callosum,	   caudate	   putamen	   and	   hippocampus	   [30].	   These	   early	   remarkable	   changes	  
may	  reflect	  widespread	  changes	  to	  the	  myelin	  structure	  [186].	  However,	  as	  the	  disease	  progressed	  
and	  during	  the	  chronic	  stages	  of	  the	  disease	  cycle	  (28	  days	  post	   immunization),	  the	  reduction	   in	  
MTR	   values	   was	   not	   significant,	   which	   could	   indicate	   less	   structural	   damage,	   initiation	   of	   the	  
myelin	  repairing	  mechanism,	  or	  inter-­‐individual	  variability	  between	  mice	  at	  the	  chronic	  stage	  [30].	  	  
On	   the	  other	  hand,	  using	   chronic	  MOG	   induced	  mouse	  models	  of	  MS,	   there	  was	  a	   reduction	   in	  
MTR	   during	   three	   stages	   (	   11,	   17	   and	   28	   days	   post	   immunisation)	   [30].	   This	   emphasises	   the	  
importance	   of	   structural	   and	   axonal	   damage	   as	   a	   primary	   pathological	   process	   in	   the	   MOG-­‐
induced	  model.	  This	  study	  confirms	  changes	  observed	   in	  a	  previous	  microscopic	  and	  histological	  
study	   of	   the	   spinal	   cord	   using	   the	   same	   EAE	   model	   [186,	   187].	   Also,	   in	   the	   same	   study,	  
hematoxylin	  and	  eosin	  (H	  &E)	  staining	  detected	  perivascular	  parenchymel	  cellular	  infiltration.	  LFB	  
additionally	   demonstrated	   demyelination	   in	   the	   brain	   stem,	   thalamus	   and	   corpus	   callosum[30].	  
Glatiramer	   acetate	   (GA)	   has	   been	   given	   to	   both	   the	   relapsing	   remitting	   PLP	   and	   chronic	  MOG	  
groups	  where	  the	  MTR	  values	  showed	  pseudonormalisation	  or	  recovery	  toward	  the	  normal	  values	  
in	  both	  groups.	  These	  results	  support	  the	  role	  of	  MTR	  imaging	  as	  a	  marker	  of	  remyelination	  [30].	  	  	  
3.5. Susceptibility Weighted Imaging (SWI) 
Susceptibility	   differences	   between	   tissues	   offers	   a	   unique	   contrast	   [188].	   SWI	   is	   based	   on	   T2*	  
weighted	   imaging,	   but	   consists	   of	   magnitude	   and	   phase	   information	   [189].	   At	   sufficiently	   long	  
echo	   time	   (TE),	   the	   signals	   from	   white	   and	   grey	   matter,	   due	   to	   their	   different	   magnetic	  
susceptibility,	  become	  out	  of	  phase.	  Therefore,	  phase	  imaging	  can	  be	  used	  to	  enrich	  the	  contrast	  
between	   tissue	   types	   as	  well	   as	   accentuating	   iron	   laden	   tissues	   and	   venous	  blood	   vessels	   [189,	  
190].	  
A	  recent	  MS	  imaging	  study	  using	  T2*	  weighted	  imaging	  at	  7T	  [191]	  has	  explored	  the	  relationship	  
between	  MS	  lesions	  and	  deep	  veins.	  The	  occurrence	  of	  plaque	  in	  association	  with	  deep	  veins	  has	  
been	  established	  in	  previous	  histopathological	  studies,	  where	  the	  presence	  of	  the	  central	  vein	  or	  
venule	   in	   the	  white	  matter	   lesion	  were	   suggested	   to	   be	   a	   distinctive	  marker	   for	   differentiating	  
between	  demyelinated	  MS	  lesions	  and	  non-­‐MS	  lesions	  [191].	  	  
However,	  this	  technique	  requires	  investigation	  at	  lower	  field	  strength	  to	  assess	  its	  sensitivity	  in	  a	  
clinically	   relevant	   environment.	   Susceptibility	   weighted	   angiography	   at	   3T	   [192]	   showed	   that	  
central	  veins	  could	  be	  correlated	  with	  white	  matter	  lesions	  (WML)	  with	  or	  without	  demyelination.	  
Therefore,	   distinguishing	   the	   origin	   of	   central	   vein	   WML	   from	   MS	   or	   other	   neuropathological	  





	   	  
	  
	  
Figure	   9.	   Magnetisation	   transfer	   application	   to	   study	   pathological	   changes	   in	   both	   MOG	   and	   PLP	   models	  
Comparisons	  between	  (A)	  chronic	  MOG	  and	  (B)	  relapsing	  remitting	  (RR)	  PLP	  EAE	  induced	  models	  during	  MS	  cycle.	  (C)	  
Whole	  brain	  MTR	  histogram	  shows	  reduction	  of	  MTR	  values	  in	  both	  groups	  but	  there	  was	  variability	  of	  the	  MTR	  values	  
in	  the	  RR-­‐PLP	  EAE	  group	  [30].	  
The	  role	  of	  perivenous	  space	  in	  developing	  MS	  lesion	  is	  still	  controversial	  [85,	  193,	  194].	  Dynamic	  
contrast	   enhanced	   studies	  may	  provide	  a	  better	  understanding	  of	   the	   relationship	  between	   the	  
central	  vein	  and	  MS	  lesions.	  Disruption	  of	  the	  blood	  brain	  barrier	  (BBB)	  is	  an	  early-­‐established	  MS	  
lesion	  formation	  indicator	  [195].	  However,	  it	  is	  not	  well	  defined	  whether	  the	  BBB	  disruption	  is	  the	  
primary	   event	   that	   leads	   to	   lesion	   formation,	   or	   a	   secondary	   event	   that	   occurs	   after	   diffuse	  
parenchymal	   tissue	   damage	   [85].	   A	   recent	   study	   [195]	   has	   explored	   two	   patterns	   of	   enhanced	  
lesions:	   new	   lesions	   tend	   to	   enhance	   centrifugally	   and	   established,	  whereas	   old	   lesions	   tend	   to	  
enhance	  centripetally.	  This	  observation	  may	  be	  significant	  in	  resolving	  questions	  between	  opening	  
and	  closing	  of	  the	  BBB	  with	  the	  central	  vein	  in	  MS	  lesion;	  and	  also	  establishing	  whether	  vascular	  
permeability	   could	   be	   used	   as	   a	   distinctive	   surrogate	   distinctive	   marker	   of	   acute	   and	   chronic	  
lesions	  [194].	  
SWI	   hypointense	   lesions	   have	   been	   demonstrated	   in	   EAE	   mice	   immunized	   with	   MOG35-­‐55,	  
complete	  Freud’s	  adjuvant	  (CFA)	  and	  pertussis	  toxin	  (PT)	  [196].	  These	  lesions	  were	  more	  prevalent	  
in	  the	  lumbar	  spinal	  cord	  and	  cerebellum	  during	  the	  peak	  of	  disease	  severity	  at	  around	  days	  16-­‐19,	  
as	  well	  as	  during	  long-­‐term	  imaging	  at	  day	  30	  up	  to	  6	  months	  (figure	  10).	  In	  addition,	  some	  of	  the	  
lesions	  were	  no	  longer	  visible	  following	  perfusion;	  the	  percentages	  of	  the	  remaining	  lesions	  after	  
perfusion	  were	  60.1	  %	  and	  46.6%	  in	  the	  spinal	  cord	  and	  cerebellum	  respectively.	  This	  could	  be	  an	  
indicator	   of	   the	   role	   of	   deoxyhemoglobin	   in	   the	   lumen	   vessels,	   in	   which	   they	   would	   have	  
disappeared	  in	  ex-­‐vivo	  imaging	  [196].	  Histopathology	  analyses	  of	  SWI	  hypointense	  lesions	  revealed	  
iron	   deposition,	   inflammation	   and	   demyelination	   within	   the	   white	  matter	   of	   the	   lumbar	   spinal	  




Figure	  10.	  Visualization	  of	  SWI	  hypointense	   lesions	   in	   the	  cerebellar	  white	  matter	  of	  EAE	  mice,	  MS	   lesions	  can	  be	  
observed	  in	  SWI	  (zoomed	  column)	  during	  the	  peak	  EAE	  (18	  days	  post	  immunisation)	  and	  long-­‐term	  disease	  progression	  
(6	  months	   post	   immunisation).	   These	   lesions	   (black	   arrows)	   have	   not	   been	   detected	   in	   the	   naive	   and	   control	  mice	  
immunized	   with	   complete	   Freud	   adjuvant	   and	   pertussis	   toxin.	   SWI	   was	   acquired	   using	   3D	   gradient	   echo	   flow	  
compensated	   at	   9.4T,	   imaging	   parameters:	   TR/TE=	   50/4	   ms,	   FA=15°,	   NEX=17,	   FOV=0.92×1.28×1.28,	   voxel	  
size=48×100×400	  μm)	  [196].	  
4. Conclusion  
This	   review	   paper	   provides	   an	   overview	   of	   recent	   developments	   in	   MRI	   modalities	   tailored	   to	  
investigation	  of	  specific	  aspects	  of	  MS	  using	  animal	  models	  and	  to	  enhance	  diagnostic	  accuracy	  in	  
patients.	   These	   recent	  MRI	   developments	   include	   the	   introduction	   of	  more	   sensitive	   cryogenic	  
coils	  and	  imaging	  at	  higher	  field	  strength.	  	  
Key	  aspects	  of	  MS	   that	   can	  be	  monitored	  by	  MRI	   include	  BBB	   leakage,	   immune	  cell	   infiltration,	  
inflammation,	   demyelination,	   axonal	   injury,	   and	   changes	   in	   brain	   connectivity	   and	   structural	  
volumes	   [1].	   In	   addition	   to	   these	  pathological	   changes,	   remyelination,	  which	   is	   observed	  during	  
the	   chronic	   stage,	   can	  be	   a	   significant	   biomarker	   of	   restoration	  of	   nervous	   system	   functionality	  
[197].	   Also,	   vascular	   permeability	   can	   be	   considered	   as	   a	   distinctive	   marker	   for	   distinguishing	  
between	  acute	  and	  chronic	  MS	  lesions	  [194].	  	  	  	  
In	   the	   clinical	   setting,	   conventional	  MRI	   techniques	   have	   been	   employed	   to	   detect	   established	  
lesions	   in	   chronic	  MS,	   but	   are	   generally	   insensitive	   during	   the	   initial	   stages	   of	   the	   disease	   [15].	  
Optimised	   methods	   such	   as	   FLAIR	   and	   DIR	   at	   high	   magnetic	   field	   strength	   provide	   improved	  
sensitivity	  for	  detection	  of	  cortical	  lesions	  [20].	  DWI	  can	  also	  detect	  such	  changes	  with	  additional	  
advantages:	   (i)	   sensitivity	   for	   detection	  of	   early	  MS	  especially	   in	   the	  normal-­‐appearing	  white	  or	  
grey	  matter;	  and	  (ii)	  detection	  of	  changes	   in	  brain	  connectivity	  and	  fibre	  density	  with	  significant	  
correlation	  with	  patient	  disability	  status	  [20,	  134].	  MTR	  is	  sensitive	  to	  changes	  in	  myelin	  content,	  
and	   appears	   useful	   to	   differentiate	   demyelinated	   from	   remyelinated	   lesions	   [35].	   SWI	   provides	  
unique	   contrast	   either	   based	   on	   T2*	   or	   susceptibility	   changes	   and	  may	   become	   an	   increasingly	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important	   technique,	   particularly	   at	   higher	   field	   strength	   [198].	   There	   are	   several	   controversial	  
imaging	  markers	   that	   have	   been	   proposed	   from	   SWI	   studies	   such	   as	   central	   vein	   detection	   but	  
they	  require	  lengthy	  longitudinal	  studies	  and	  standardized	  imaging	  protocols	  [192].	  	  	  
Longitudinal	  MRI	   imaging	  of	  rodent	  models	  of	  MS	  facilitate	   investigation	  of	  temporal	  changes	   in	  
the	  brain	  during	  progression	  from	  the	  acute	  to	  the	  chronic	  stages	  of	  MS	  disease.	  In	  general,	  MRI	  
findings	  observed	  in	  patients	  with	  MS	  patients	  have	  been	  similarly	  observed	  in	  rodent	  models	  of	  
MS.	   	   These	   include	   T2	   hypointensity	   of	   the	   deep	   grey	   matter	   lesions	   [93],	   USPIO	   detection	   of	  
immune	  cell	  infiltration	  [117],	  reduction	  in	  FA	  due	  demyelination	  [77]	  and	  brain	  atrophy	  [32].	  	  
Table	  2.	  Correlation	  between	  MRI	  observations	  in	  patients	  with	  MS	  and	  rodent	  models	  
MRI	  observations	  	   Human	  MS	  studies	   Rodent	  MS	  studies	  
T1	  WI	  hypointensity	  
lesions	  
For	  detection	  of	  advanced	  
MS	  lesions	  [15].	  
Detected	  in	  the	  TMEV	  mouse	  
model	  to	  investigate	  the	  role	  of	  
the	  adaptive	  immune	  system	  
[80].	  
T2	  WI	  hypointensity	  
lesions	  in	  the	  deep	  grey	  
matter	  
Good	  correlation	  with	  
clinical	  disabilities	  [95,	  96].	  
Requires	  detection	  using	  
high	  magnetic	  field,	  such	  
that	  it	  may	  be	  difficult	  to	  
apply	  in	  the	  setting.	  	  
Observed	  in	  the	  TMEV	  mouse	  
model	  and	  could	  be	  useful	  for	  
efficacy	  assessment	  of	  novel	  MS	  
treatments	  [93].	  
Changes	  in	  brain	  volumes	   Distinct	  biomarker	  for	  
advanced	  disease	  
progression	  [87-­‐89].	  
In	  EAE	  mouse	  model,	  the	  loss	  of	  
cortical	  volume	  was	  due	  to	  loss	  
of	  Purkinje	  cells	  in	  the	  molecular	  
cortex	  [32,	  78].	  
USPIO	  enhancement	  	   An	  indicator	  of	  immune	  cell	  
infiltration	  [120].	  
Observed	  in	  the	  relapsing	  
remitting	  EAE	  mouse	  model	  of	  
MS;	  linked	  with	  presence	  of	  
macrophages	  and	  demyelination	  
[117].	  	  
Central	  veins	  observed	  
on	  T2*	  WI	  and	  
hypointensity	  on	  SWI	  
Distinctive	  imaging	  markers	  
in	  determining	  MS	  
demyelinated	  and	  non-­‐
demyelinated	  lesions	  [191]	  
These	  lesions	  observed	  in	  the	  
lumbar	  spinal	  cord	  and	  







Table	  3.	  Summary	  of	  MRI	  observations	  and	  pathological	  correlations	  
Technique	   MRI	  changes	  
in	  patients	  
with	  MS	  
Pathobiological	  correlations	   References	  
T1	  WI	   Hypo-­‐intensity	   Severity	  of	  tissue	  damage	  	   [80,	  104,	  134]	  
T2	  WI	   Hyper-­‐intensity	   Active	  (developing)	  MS	  lesions	  	   [13,	  82]	  
T1	  pre/post	  
contrast	  
Hypo-­‐intensity	   Combination	  of	  demyelination	  and	  axonal	  
loss	  	  
[15,	  27,	  199]	  
T1	  post	  
contrast	  
Hyper-­‐intensity	   Permeability	  of	  the	  blood	  brain	  barrier	  and	  
activity	  of	  MS	  lesions	  
[34,	  102,	  120]	  
MTR	   Decrease	   Progressive	  demyelination	  over	  time	   [35,	  174,	  185]	  
Increase	   Partial	  remyelination	  within	  active	  MS	  
lesion	  
MD	   Increase	   Extracellular	  oedema	  and	  inflammation	   [122]	  
FA	   Decrease	   Lower	  axonal	  bundle	  coherence	  in	  WM	  










Demyelination	  	   [139,	  140,	  146]	  
MTR	   Decrease	   Progressive	  demyelination	  over	  time	   [150]	  
Increase	   Partial	  remyelination	  within	  active	  MS	  
lesions	  
	  
SWI	   Central	  veins	  in	  
the	  MS	  lesion	  on	  
T2*WI	  
Distinctive	  marker	  of	  demyelinated	  and	  non	  
demyelinated	  lesions	  	  
[192]	  
Hypointense	  
lesions	  on	  SWI	  
images	  
Distinguishing	  biomarker	  of	  active	  and	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